Israeli researchers have developed a treatment that can prevent developmental lag and autism, the University of Tel Aviv University reported on Thursday.
The researchers found that early therapy with the NAP peptide (nucleosome montage protein) normalized the development of mice in the ADNP (actively dependent neuroprotective protein) syndrome in children.
This genetic mutation is one of the main causes of the development of delay and autism in children.
ADNP gene plays a role in the development of cognition. Embryos with a partial disadvantage of ADNP will suffer from mental retardation and, in most cases, autism.
In recent years, with the development of genetic sequencing technology, autistic children with mental retardation have had random mutations in the ADNP gene that occur during pregnancy.
The resulting protein is shorter than usual, and as a result, children suffer from incomplete ADNP (which is ADNP syndrome).
The researchers found that mice with ADNP produce only about half the number of synapses (connections between nerve cells) compared to healthy mice – especially in areas of the brain responsible for cognitive activity, according to the report.
These mice showed delay in development, social difficulties and sensitivity, such as children with mental retardation and autism.
In the next stage, the NAP peptide is injected daily into infected mice from the moment of birth, and then the breast mite is mixed with breastfeeding.
The results were very impressive: treated mice, unlike those who were not treated, are normally developed. They made voices to call their mothers, walk, have proper memory, they could distinguish famous and unknown mice and developed muscle strength.
It also turned out that the brains of these mice began to produce the corresponding number of synapses.